CN101597314A - A kind of ginsenoside Rg 1The preparation method - Google Patents
A kind of ginsenoside Rg 1The preparation method Download PDFInfo
- Publication number
- CN101597314A CN101597314A CNA2008101146861A CN200810114686A CN101597314A CN 101597314 A CN101597314 A CN 101597314A CN A2008101146861 A CNA2008101146861 A CN A2008101146861A CN 200810114686 A CN200810114686 A CN 200810114686A CN 101597314 A CN101597314 A CN 101597314A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- filtrate
- eluent
- ethanol elution
- filters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of ginsenoside Rg
1The preparation method of effective constituent is characterized in that different medicinal materials are obtained total saponins, and the method that adopts macroporous adsorbent resin method and organic solvent extraction to organically combine obtains purity more than or equal to 90% ginsenoside Rg
1, this method is fit to suitability for industrialized production, can obtain the ginsenoside Rg of feather weight
1, have the high characteristics of extraction yield; Pharmacological evaluation shows, the ginsenoside Rg that the inventive method obtains
1Has good drug action.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, be specifically related to a kind of ginsenoside Rg
1The preparation method of effective constituent.
Background technology
The ginsenoside Rg
1Be mainly derived from Araliaceae Panax genseng, pseudo-ginseng, four American ginsengs, Vietnam's genseng, rhizome of Japanese Ginseng; in the root of plants such as Curcurbitaceae gynostemma pentaphyllum genus gynostemma pentaphylla, edge fruit gynostemma pentaphylla, stem, leaf, the bud; have good pharmacologically active: (1) is to the provide protection of myocardial ischemia-reperfusion; studies show that the ginsenoside Rg
1Can reduce SD suckling mouse myocardial ischemia cells injury, performance is to the provide protection of myocardial ischemia-reperfusion; (2) to the provide protection of cerebral ischemia, the ginsenoside Rg
1Can be by improving the animal microcirculation cerebral blood flow increasing amount, performance improves the effect of cerebral ischemia; (3) has anti thrombotic action, the ginsenoside Rg
1Can obviously reduce experimental thrombosis and form, can Trombin inhibiting inductive platelet aggregation; (4) have anti-mutation and antitumor action, ginsenoside Rg
1Dna damage to somatocyte and sexual cell all has provide protection, and mice transplanted tumor is also had certain tumor-inhibiting action; (5) have antifatigue and resisting oxygen lack, ginsenoside Rg
1Mouse anti-reflecting fatigue and hypoxia tolerance there is obvious effects; (6) has the effect of anti-hemorrhagic shock; Or the like.
In sum, ginsenoside Rg
1Have significantly and widely pharmacologically active, the patent medicine basis is good.But prepare at present the ginsenoside Rg
1Method mostly be laboratory method, only can obtain a small amount of ginsenoside Rg
1(the mg level is to the g level) for scientific research usefulness, is difficult to obtain the in batches ginsenoside Rg of level (feather weight)
1, therefore, at first explore and suitability for industrialized production to obtain the in batches ginsenoside Rg of level
1Preparation technology, be the ginsenoside Rg
1Can key that patent medicine and basis have important technology and market value; Its two, obtaining in batches level high-load ginsenoside Rg
1The basis on, further improve its quality, make it obtain the control of comprehensive mass of system, the medicine that it is made as active component, steady quality, curative effect is controlled with safety, is the inherent basic requirement that Chinese medicine move towards the world; Its three, the ginsenoside Rg
1As the curative effect composition, dose-effect/time-effect relationship, drug disposition dynamic metabolism and security it be unclear that, need to by researchs such as dose-effect screening and pharmacokinetics, optimize its excellent effect dosage and administering mode, and these systems' further investigations all need the in batches ginsenoside Rg of level
1Be the basis; Therefore, set up in batches grade ginseng saponin(e Rg of preparation through technological innovation
1Process, be the technical guarantee of follow-up study, needing the scientific research personnel to pay huge creative work could realize.
Application number is 03148804.8 patent documentation, and the method that the document discloses employing silica gel (or aluminium oxide) column chromatography obtains the ginsenoside Rg
1Application number is 200610093615.9,200610093610.6 patent documentation, and the document discloses and adopted the method for silica gel column chromatography, alumina column chromatography or ODS column chromatography can obtain the ginsenoside Rg
1These class methods involve great expense, and are only applicable to laboratory research, are difficult to realize suitability for industrialized production.
Summary of the invention
For these reasons, our scientific research personnel studies by scientific experiment, and technological innovation has gone out a kind of suitable suitability for industrialized production, processing method that extraction yield is high, is used to extract purified ginsenoside Rg
1, this method adopts macroporous adsorbent resin method and organic solvent extraction method to carry out organic assembling, and the total saponins that different medicinal materials are obtained further extracts purifying, obtains the ginsenoside Rg
1Content can be used to develop Chinese medicine a kind new medicine more than or equal to 90%, and has characteristics such as yield height, can obtain the ginsenoside Rg of feather weight
1, the ginsenoside Rg who makes
1Patent medicine research has had good basic substance.
The present invention is achieved through the following technical solutions.
The ginsenoside Rg
1The preparation method: get pseudo-ginseng, ginseng, American Ginseng or gynostemma pentaphylla and extract the total saponin(e that obtains, total saponin(e is dissolved in water; Lysate filters, and filtrate is washed by nonpolar or low pole large pore resin absorption column, and eluent discards, and the 20%-60% ethanol elution is collected eluent, and is concentrated, dry, obtains the ginsenoside Rg
1Crude product adds organic solvent, extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Perhaps
Get pseudo-ginseng, ginseng, American Ginseng or gynostemma pentaphylla and extract the total saponin(e that obtains, total saponin(e is dissolved in water, and filters, and filtrate is by nonpolar or low pole large pore resin absorption column, washing, eluent discards, and the 20%-60% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, and filtrate is by nonpolar or low pole large pore resin absorption column, washing, eluent discards, and uses the 10%-50% ethanol elution, and eluent discards, use again the 20%-60% ethanol elution, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Wherein the nonpolar or low-pole macroporous resin described in the preparation method includes but not limited to: HPD-100, HPD-100A, HPD-300, HPD-400, HPD-400A, HPD-450, D101,1300-I, 1400 or AB-8.
Wherein the organic solvent described in the preparation method includes but not limited to a kind of in acetone, the butanone.
Total saponins in the said extracted method can directly be bought by market or prepare according to scientific and technical literature.
The ginsenoside Rg of method for preparing
1Pharmaceutical preparation for the unitary dose of active substance preparation.
The ginsenoside Rg of method for preparing
1Treat and/or prevent application in the medicines such as cardiovascular and cerebrovascular diseases, antishock, antitumor, anti-ageing, hypomnesis in preparation.
One, ginsenoside Rg
1Content assaying method and detected result
Experimental technique: adopt high performance liquid chromatography to carry out assay;
Chromatographic column: C
18Reverse-phase chromatographic column; Chromatographic condition and system suitability experiment: with the octadecylsilane chemically bonded silica is weighting agent; Flow velocity 1.0ml/min; 25 ℃ of column temperatures; Detect wavelength 203nm; Number of theoretical plate is by the ginsenoside Rg
1Meter should be not less than 2500; With water: acetonitrile is a moving phase, carries out gradient elution by following condition of gradient elution, moves 60 minutes;
In the time of 0-40 minute, the ratio of water reduces to 50% by 80%, and the ratio of acetonitrile rises to 50% by 20%; In the time of 40-43 minute, the ratio of water reduces to 20% by 50%, and the ratio of acetonitrile rises to 80% by 50%; In the time of 43-48 minute, keeping the ratio of water is 20%, and keeping the ratio of acetonitrile is 80%; In the time of 48-50 minute, the water ratio rises to 80% by 20%, and the ratio of acetonitrile reduces to 20% by 80%; 50-60 minute keeps the ratio of water is 20%, the ratio 80% of acetonitrile;
The preparation of reference substance solution: precision takes by weighing the ginsenoside Rg
1Reference substance adds dissolve with methanol and shakes up in volumetric flask, and is diluted to scale;
The preparation of need testing solution: precision takes by weighing sample and adds dissolve with methanol in the volumetric flask and shake up, and is diluted to scale;
Assay method: accurate respectively absorption reference substance solution and need testing solution respectively inject liquid chromatograph, adopt by external standard method with calculated by peak area, promptly.
Annotate: genseng saponin(e Rg of the present invention
1Reference substance is legal product, buys from Chinese pharmaceutical biological product and identifies institute.
Get the ginsenoside Rg that preparation method of the present invention obtains
1Effective constituent is carried out check and analysis according to above-mentioned experimental technique.
Experimental result: the results are shown in Table 1:
Table 1 ginsenoside Rg
1The sample determination result
Experiment conclusion: show genseng saponin(e Rg of the present invention by above-mentioned experiment
1Content proves absolutely that more than or equal to 90% and less than 100% processing method of the present invention has scientific meaning.
Two, different process method contrast experiment
Experimental program:
Scheme 1: application number is 03148804.8 Chinese patent, disclosed embodiment in the specification sheets;
Scheme 2: application number is 200610093615.9 Chinese patent, disclosed embodiment 1 and embodiment 7 in the specification sheets;
Scheme 3: application number is 200610093610.6 Chinese patent, disclosed embodiment 1 and embodiment 7 in the specification sheets;
Scheme 4: processing method of the present invention.
Experimental technique is got the arasaponin of same batch, tests according to above-mentioned experimental program, obtains the ginsenoside Rg
1
Experimental result: the results are shown in Table 2.
The comparative experiments of table 2 different process method
Discuss: experimental program 1,2 and 3 methods that adopt are: total saponins obtains the ginsenoside Rg with Amberlyst process+silica gel (or aluminum oxide) column chromatography+silica gel column chromatography
1This method is used two step silica gel (aluminum oxide) column chromatographies, use mixed solvent and consumption of organic solvent big, solvent is difficult to recycling, and the regeneration of silica gel (aluminum oxide) is difficulty comparatively, and silica gel (or aluminum oxide) column chromatography is generally as laboratory method, preparing micro-product uses for scientific research, be used for suitability for industrialized production, product cost is very high, and the human consumer is difficult to bear; The ginsenoside Rg
1Be mainly used in the cardiovascular and cerebrovascular diseases aspect, the time that the patient uses is long, if produce the ginsenoside Rg
1Processing method numerous and diverse, cost is higher, can bring huge economical load to the patient; What scheme 4 (processing method of the present invention) adopted is Amberlyst process+organic solvent extraction method or Amberlyst process+Amberlyst process+organic solvent extraction method, the organic solvent that this method adopts is single organic solvent-acetone or butanone, toxicity is little, be beneficial to recycling, and the amount of using is also less, this method technology is simple, economical, is suitable for suitability for industrialized production.
Conclusion: show that by above-mentioned experiment the poisonous organic solvent amount that processing method of the present invention is used is few, low to the operating space requirement, environmental pollution is less, has the high characteristics of yield, proves absolutely that processing method of the present invention has scientific meaning.
Annotate: the total saponins of medicinal materials such as above-mentioned Radix Notoginseng total arasaponins and genseng, gynostemma pentaphylla, Radix Panacis Quinquefolii is replaced, and experiment conclusion is identical with above-mentioned experiment conclusion.
Three, pharmacological effect experiment
The provide protection of 1 pair of anesthetized rat myocardial ischemia-reperfusion injury of experiment.
Laboratory animal: healthy SD rat, body weight 240-260g.
Experiment medicine: physiological saline; Genseng saponin(e Rg of the present invention
1Effective constituent.
Experiment reagent: 20% urethane is pressed; The tincture of iodine; Test kit; 1%TTC.
Laboratory apparatus: respirator; Electrocardiograph; The ophthalmology tweezer; Automatic clinical chemistry analyzer; Digital camera.
Experimental technique: with the rat random packet: model group, ginseng saponin(e Rg of the present invention
1Group.Place the pre-raising of equivalent environment 2 days, free diet.After pre-raising finishes, test, animal is weighed, and 20% urethane is pressed the 0.6ml/100g lumbar injection, after treating that anesthesia is satisfied, lie on the back and be fixed on the mouse plate, trachea cannula connects lung ventilator, by 10～12ml tidal volume, 70 times/minute frequency is exhaled, and continuous positive pressure breathing is inhaled: exhale than being 1: 1.Adjust respiration parameter according to the respiratory rate and the degree of depth.Connect electrocardiograph subsequently, survey normal ECG.Cut off front field of operation hair, iodine disinfection, cut off skin, subcutis, front muscle and manadesma 3～4cm, it is long to separate intercostal muscle 3cm with the 18# vascular clamp along the 3rd intercostal passivity, open thoracic cavity and pericardium, recording ecg, strut 3,4 ribs, refer to hold thoracic cavity, rat right side with left hand four, the assistant upwards pushes away thymus gland with the ophthalmology tweezer, finds ligation sign blood vessel great cardiac vein between left auricle of heart and pulmonary conus, the 2mm place is with there not being wound roundlet pin band 6-0 silk thread threading below left auricle of heart, depth of needle is 1～1.5mm, wide 2～3mm, recording ecg behind the threading, give corresponding soup through the tail vein, recording ecg behind the administration 10min, and with one the band groove little plastics pipe pad at the ligation position, the ligation thereon of two rear line heads.At once recording ecg after the ligation is cyanosis or the II S-T section back of a bow that leads take left chamber antetheca and upwards raises greater than 0.1mv and more than the lasting 0.5h and successfully indicate (it is superseded that the S-T section does not have the changer) for ligation.10min recording ecg is again cut off ligature behind the ligation 30min after the ligation, realizes again perfusion, and record pours at once electrocardiogram again, removes in the thoracic cavity layer-by-layer suture wall of the chest behind the hematocele, removes lung ventilator, animal recovery autonomous respiration, and incision of trachea does not process.Irritate again at once, 10min, 20min, 40min, 1h, 2h, 3h recording ecg respectively.Irritated again 3 hours, through abdominal aortic blood, 4000rpm is centrifugal, and 10min gets serum, adopt automatic clinical chemistry analyzer to detect LDH, CK and CK-MB activity, and adopt the corresponding reagent box to detect SOD in serum, MDA (above index specifically detects step and sees specification sheets for details), dissection is cored dirty, the residual blood of ice physiological saline flush away, cut off atrium and right ventricle, put into refrigerator and cooled immediately and freeze.With heart after refrigerator and cooled is frozen 10min, from the apex of the heart entad the parallel coronary sulcus direction in the end 5 of equal thickness are cut in left chamber, put into the 1%TTC dye liquor, 37 ℃ of dyeing 10min, the necrotic area is not a garnet, the necrotic area is canescence.Digital camera is taken pictures.Weighed respectively in necrotic area and non-necrotic area, calculate the per-cent that the necrotic area accounts for left ventricular mass, i.e. infarction size.
Experimental result: the results are shown in Table 3.
The influence of myocardial ischemia myocardial infarct size (%) due to table 3 pair ligation/logical again rat ramus descendens anterior arteriae coronariae sinistrae
Annotate: compare * * P＜0.01 with model group.
The research of 2 pairs of focal cerebral ischemia-reperfusion Injury model of Wistar rats protective effects of experiment
Laboratory animal: the wistar rat, male, body weight is about 250g.
Experiment medicine: physiological saline; Genseng saponin(e Rg of the present invention
1Effective constituent.
Experiment reagent: heparin; Formaldehyde; The TTC dye liquor.
Laboratory apparatus: big flat; Vacuum drier; Refrigerator.
Experimental technique: with the animal random packet: blank group, genseng saponin(e Rg of the present invention
1The effective constituent group.Genseng saponin(e Rg of the present invention
1The each 8.0mg/kg of effective constituent group dosage, the blank group gives physiological saline.Administration group and control group successive administration 3 days, every day 1 time.Made middle cerebral artery occlusion (MCAO) model with improvement line bolt method in 20 minutes behind the 4th day medicine.Behind the rat anesthesia, it is fixing that it is lain on the back.Separate right carotid (CCA), internal carotid artery (ICA) and external carotid artery (ECA), ligation ECA and CCA, after closing the ICA distal end with bulldog clamp folder, make a kerf in ECA and ICA crotch rapidly, insert the nylon wire (diameter is 0.25mm, marks apart from pommel 18mm place, is stained with heparin solution before the insertion) that an end is heated into smooth, spherical and has been coated with 0.1% poly-lysine, depth of penetration is 18mm, realizes that middle cerebral artery occlusion causes cerebral ischemia.Ligation ingress, nylon wire are stayed about 1cm, skin suture outward.Lift extremely slightly resistance of institute's the end of a thread that stays after 2 hours gently, realize that arteria cerebri media pours into again, modeling is finished.At ischemic 2h with pour into the body temperature of keeping rat in the 1h with electric blanket again, body temperature maintains 36.5～37.5 ℃ of anus temperature.The animal inclusion criteria is pressed Longa Pyatyi point system, gets the neural function behavior scoring and be 1,2,3,4 minute animal, (0 minute: the impassivity defective symptom; 1 minute: the offside forelimb can not stretch fully; 2 minutes: to sideway swivel; 3 minutes: topple over to offside; 4 minutes: can not oneself walk or stupor).The cerebral infarction scope is measured, rat model pours into 24h again, after the study of behaviour scoring, broken end is got brain, removes olfactory bulb, cerebellum and low brain stem, and remainder is at-20 ℃ of freezing 10min of refrigerator, crownly on ice pan be cut into 6, rapidly the brain sheet is placed the TTC dye liquor, 37 ℃ of lucifuge temperature are incubated 1h, take out to be placed on the 24h that keeps in Dark Place in 10% formalin.Dyed rear non-ischemic region is rose, and infarct is white.White organized carefully to dig down weigh, account for full brain weight percentage as Range of Cerebral Infarction with blocking tissue's weight.
Brain water content is measured: after TTC dyeing is weighed, brain placed oven dry 12h claims dry weight in 120 ℃ of vacuum desiccators.Brain water content=(brain weight in wet base-brain stem is heavy)/brain weight in wet base * 100%.
Experimental result: the result sees table 4 for details.
The impact of table 4 pair focal cerebral ischemia-reperfusion Injury model of Wistar rats rat cerebral infarction scope and brain water content
Annotate: compare * * P＜0.01 with the blank group.
Annotate: with the ginsenoside Rg of the inventive method preparation
1Active ingredient is carried out the pharmacological effect experiment of the aspects such as antitumor, anti-shock, anti-ageing, failure of memory, and the result shows, the ginsenoside Rg of the inventive method preparation
1Active ingredient and control group have utmost point significant difference (P＜0.01).
Experiment conclusion: show the ginsenoside Rg of the inventive method preparation by the pharmacological effect experiment
1Effective constituent and control group relatively have utmost point significant difference (P＜0.01), prove absolutely that processing method of the present invention has practical significance.
Four, preparation embodiment
Embodiment 1
Get pseudo-ginseng and extract the arasaponin obtain and be dissolved in water, filter, filtrate is by the HPD-400A large pore resin absorption column, washing, eluent discards, and 20% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400A large pore resin absorption column, and eluent discards, use 10% ethanol elution, eluent discards again, and uses 20% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
The method that pseudo-ginseng is extracted total saponin(e is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 2
Get ginseng and extract the total saponin(e obtain and be dissolved in water, filter, filtrate is by the HPD-400 large pore resin absorption column, washing, eluent discards, and 60% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400 large pore resin absorption column, and eluent discards, use 50% ethanol elution, eluent discards again, and uses 60% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent butanone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 3
Get American Ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the HPD-300 large pore resin absorption column, washing, eluent discards, and 25% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-300 large pore resin absorption column, and eluent discards, use 15% ethanol elution, eluent discards again, and uses 25% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent n-butanol, ethanol, methyl alcohol extraction, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 4
Get pseudo-ginseng and extract the total saponin(e obtain and be dissolved in water, filter, filtrate is by the HPD-450 large pore resin absorption column, washing, eluent discards, and 55% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-450 large pore resin absorption column, and eluent discards, use 45% ethanol elution, eluent discards again, and uses 55% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
The extracting method of described arasaponin can be led to the existing patent documentation of basis or scientific and technical literature is prepared.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 5
Get gypenosides and be dissolved in water, filter, filtrate is washed by the HPD-100A large pore resin absorption column, eluent discards, and 30% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100A large pore resin absorption column, and eluent discards, use 20% ethanol elution, eluent discards again, and uses 30% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent butanone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described gypenosides prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 6
Get general ginsenoside and be dissolved in water, filter, filtrate is washed by the D101 large pore resin absorption column, eluent discards, and 35% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the D101 large pore resin absorption column, and eluent discards, use 25% ethanol elution, eluent discards again, and uses 35% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 7
Get American ginseng total saponins and be dissolved in water, filter, filtrate is washed by the HPD-100A large pore resin absorption column, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100A large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins is by commercially available purchase.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 8
Get arasaponin and be dissolved in water, filter, filtrate is washed by the 1300-I large pore resin absorption column, eluent discards, and 45% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the 1300-I large pore resin absorption column, and eluent discards, use 35% ethanol elution, eluent discards again, and uses 50% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins according to existing patent documentation or scientific and technical literature prepare (Yang Chongren, kingdom swallow, 5 jewels, etc., the saponin component of pseudo-ginseng reed head, pharmacy circular, 1985,20 (6): 337-338).
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 9
Get ginseng and extract the total saponin(e obtain and be dissolved in water, filter, filtrate is by the HPD-100 large pore resin absorption column, washing, eluent discards, and 50% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100 large pore resin absorption column, and eluent discards, use 45% ethanol elution, eluent discards again, and uses 55% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent ethyl acetate, methyl alcohol extraction, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 10
Get American ginseng total saponins and be dissolved in water, filter, filtrate is washed by 1400 large pore resin absorption columns, eluent discards, and 60% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by 1400 large pore resin absorption columns, and eluent discards, use 10% ethanol elution, eluent discards again, and uses 30% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent butanone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 11
Get pseudo-ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the AB-8 large pore resin absorption column, washing, eluent discards, and 25% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by non-AB-8 large pore resin absorption column, and eluent discards, use 40% ethanol elution, eluent discards again, and uses 60% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 12
Get pseudo-ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the AB-8 large pore resin absorption column, washing, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the AB-8 large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 13
Get gypenosides and be dissolved in water, filter, filtrate is washed by the HPD-100 large pore resin absorption column, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100 large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described gypenosides prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 14
Get arasaponin and be dissolved in water, filter, filtrate is washed by the AB-8 large pore resin absorption column, eluent discards, and 35% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the AB-8 large pore resin absorption column, and eluent discards, use 35% ethanol elution, eluent discards again, and uses 55% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin is by commercially available purchase,
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 15
Get pseudo-ginseng and extract the arasaponin obtain and be dissolved in water, filter, filtrate is by 1400 large pore resin absorption columns, washing, eluent discards, and 20% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by 1400 large pore resin absorption columns, and eluent discards, use 15% ethanol elution, eluent discards again, and uses 30% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin preparation method is prepared according to existing patent documentation or scientific and technical literature;
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 16
Get pseudo-ginseng and extract the arasaponin obtain and be dissolved in water, filter, filtrate is by the HPD-100A large pore resin absorption column, washing, eluent discards, and 55% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100A large pore resin absorption column, and eluent discards, use 50% ethanol elution, eluent discards again, and uses 60% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 17
Get pseudo-ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the 1300-I large pore resin absorption column, washing, eluent discards, and 50% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the 1300-I large pore resin absorption column, and eluent discards, use 15% ethanol elution, eluent discards again, and uses 30% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone, ethyl acetate extraction, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 18
Get ginseng and extract the total saponin(e obtain and be dissolved in water, filter, filtrate is by the D101 large pore resin absorption column, washing, eluent discards, and 30% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the D101 large pore resin absorption column, and eluent discards, use 45% ethanol elution, eluent discards again, and uses 60% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
The extracting method of described general ginsenoside can be led to the existing patent documentation of basis or scientific and technical literature prepares.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 19
Get gypenosides and be dissolved in water, filter, filtrate is washed by the HPD-300 large pore resin absorption column, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-300 large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described gypenosides prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 20
Get arasaponin and be dissolved in water, filter, filtrate is washed by the HPD-450 large pore resin absorption column, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-450 large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 21
Get pseudo-ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the HPD-400 large pore resin absorption column, washing, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400 large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins extracting method prepares according to existing document.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 22
Get ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the HPD-400 large pore resin absorption column, washing, eluent discards, and 45% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400 large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 23
Get pseudo-ginseng and extract the total saponin(e obtain and be dissolved in water, filter, filtrate is by the HPD-100A large pore resin absorption column, washing, eluent discards, and 35% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-100A large pore resin absorption column, and eluent discards, use 25% ethanol elution, eluent discards again, and uses 45% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned Panax Notoginseng saponin R g
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 24
Get arasaponin and be dissolved in water, filter, filtrate is washed by the HPD-400 large pore resin absorption column, eluent discards, and 45% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-400 large pore resin absorption column, and eluent discards, use 25% ethanol elution, eluent discards again, and uses 35% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 25
Get ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the HPD-450 large pore resin absorption column, washing, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the HPD-450 large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 26
Get ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the 1300-I large pore resin absorption column, washing, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the 1300-I large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 27
Get arasaponin and be dissolved in water, filter, filtrate is washed by the AB-8 large pore resin absorption column, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by the AB-8 large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 28
Get arasaponin and be dissolved in water, filter, filtrate is washed by the D101 large pore resin absorption column, eluent discards, and 40% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by nonpolar or low pole large pore resin absorption column, and eluent discards, use 30% ethanol elution, eluent discards again, and uses 40% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin is by commercially available purchase.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 29
Get pseudo-ginseng and extract the arasaponin obtain and be dissolved in water, filter, filtrate is by the HPD-400A large pore resin absorption column, washing, and eluent discards, and 20% ethanol elution is collected eluent, concentrates, dry, gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
The method that pseudo-ginseng is extracted total saponin(e is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside is as Rg
1Medicine material can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 30
Get ginseng and extract the total saponin(e obtain and be dissolved in water, filter, filtrate is by the HPD-400 large pore resin absorption column, washing, and eluent discards, and 60% ethanol elution is collected eluent, concentrates, dry, gets the ginsenoside Rg
1Crude product adds the organic solvent butanone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 31
Get American Ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the HPD-300 large pore resin absorption column, washing, and eluent discards, and 25% ethanol elution is collected eluent, concentrates, dry, gets the ginsenoside Rg
1Crude product adds the organic solvent butanone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 32
Get pseudo-ginseng and extract the total saponin(e obtain and be dissolved in water, filter, filtrate is by the HPD-450 large pore resin absorption column, washing, and eluent discards, and 55% ethanol elution is collected eluent, concentrates, dry, gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
The extracting method of described arasaponin can be led to the existing patent documentation of basis or scientific and technical literature is prepared.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 33
Get gypenosides and be dissolved in water, filter, filtrate is by the HPD-100A large pore resin absorption column, washing, eluent discards, 30% ethanol elution is collected eluent, concentrates, dry, do the ginsenoside Rg
1Crude product adds the organic solvent butanone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described gypenosides prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 34
Get general ginsenoside and be dissolved in water, filter, filtrate is washed by the D101 large pore resin absorption column, and eluent discards, and 35% ethanol elution is collected eluent, and is concentrated, dry, gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 35
Get American ginseng total saponins and be dissolved in water, filter, filtrate is washed by the HPD-100A large pore resin absorption column, and eluent discards, and 40% ethanol elution is collected eluent, and is concentrated, dry, gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins is by commercially available purchase.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 36
Get arasaponin and be dissolved in water, filter, filtrate is washed by the 1300-I large pore resin absorption column, and eluent discards, and 45% ethanol elution is collected eluent, and is concentrated, dry, gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described Radix Notoginseng total arasaponins according to existing patent documentation or scientific and technical literature prepare (Yang Chongren, kingdom swallow, 5 jewels, etc., the saponin component of pseudo-ginseng reed head, pharmacy circular, 1985,20 (6): 337-338).
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 37
Get ginseng and extract the total saponin(e obtain and be dissolved in water, filter, filtrate is by the HPD-100 large pore resin absorption column, washing, and eluent discards, and 50% ethanol elution is collected eluent, concentrates, dry, gets the ginsenoside Rg
1Crude product adds organic solvent ethyl acetate, methyl alcohol extraction, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described general ginsenoside extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 38
Get American ginseng total saponins and be dissolved in water, filter, filtrate is washed by 1400 large pore resin absorption columns, eluent discards, and 60% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by 1400 large pore resin absorption columns, and eluent discards, use 10% ethanol elution, eluent discards again, and uses 30% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds the organic solvent butanone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described American ginseng total saponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 39
Get pseudo-ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the AB-8 large pore resin absorption column, washing, eluent discards, and 25% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by non-AB-8 large pore resin absorption column, and eluent discards, use 40% ethanol elution, eluent discards again, and uses 60% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
Embodiment 40
Get pseudo-ginseng and extract and to obtain total saponin(e and be dissolved in water, filter, filtrate is by the AB-8 large pore resin absorption column, washing, eluent discards, 40% ethanol elution is collected eluent, concentrates, dry, do the ginsenoside Rg
1Crude product adds organic solvent-acetone and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Described arasaponin prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1As medicine material, can be prepared into acceptable pharmaceutical preparation on the pharmaceutics.
The foregoing description 1-40 obtains the ginsenoside Rg
1In the effective constituent, the ginsenoside Rg
1Content is more than or equal to 90% and less than 100%.
Above-mentioned ginsenoside Rg
1Treat and/or prevent application in cardiovascular and cerebrovascular diseases, antishock, antitumor, anti-ageing, the hypomnesis medicine in preparation.
Above-mentioned pseudo-ginseng, genseng, Radix Panacis Quinquefolii, gynostemma pentaphylla can be medicinal material root, stem, leaf, the bud in the different places of production.
Annotate: the present invention's concrete technical scheme required for protection is not limited to the concrete combination of the expressed technical scheme of the foregoing description.
Claims (3)
1, a kind of ginsenoside Rg
1The preparation method, it is characterized by:
(1) get pseudo-ginseng, genseng, Radix Panacis Quinquefolii or gynostemma pentaphylla and extract the total saponins that obtains, total saponins is dissolved in water;
(2) lysate filters, and filtrate is washed by nonpolar or low pole large pore resin absorption column, and eluent discards, and the 20%-60% ethanol elution is collected eluent, and is concentrated, dry, obtains the ginsenoside Rg
1Crude product adds organic solvent and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
Perhaps:
Lysate filters, and filtrate is washed by nonpolar or low pole large pore resin absorption column, eluent discards, and the 20%-60% ethanol elution is collected eluent, concentrated, dry, dry thing is dissolved in water, and filters, filtrate is washed by nonpolar or low pole large pore resin absorption column, and eluent discards, use the 10%-50% ethanol elution, eluent discards, and uses the 20%-60% ethanol elution again, collect eluent, concentrate drying gets the ginsenoside Rg
1Crude product adds organic solvent and extracts, and extract filters, and filtrate is reclaimed solvent to doing, and the residue drying obtains the ginsenoside Rg
1
2, a kind of ginsenoside Rg according to claim 1
1The preparation method, wherein said nonpolar or low-pole macroporous resin is HPD-100, HPD-100A, HPD-300, HPD-400, HPD-400A, HPD-450, D101,1300-I, 1400 or AB-8.
3, a kind of ginsenoside Rg according to claim 1
1The preparation method, wherein said organic solvent is a kind of in acetone, the butanone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101146861A CN101597314B (en) | 2008-06-06 | 2008-06-06 | Preparation method of ginsenoside Rg1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101146861A CN101597314B (en) | 2008-06-06 | 2008-06-06 | Preparation method of ginsenoside Rg1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101597314A true CN101597314A (en) | 2009-12-09 |
| CN101597314B CN101597314B (en) | 2012-01-04 |
Family
ID=41418930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101146861A Expired - Fee Related CN101597314B (en) | 2008-06-06 | 2008-06-06 | Preparation method of ginsenoside Rg1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101597314B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102250184A (en) * | 2010-05-21 | 2011-11-23 | 昆明制药集团股份有限公司 | Amorphous state ginsenoside Rg1 and preparation method thereof |
| CN102453072A (en) * | 2010-10-26 | 2012-05-16 | 中国医学科学院药物研究所 | Preparation method of ginsenoside Rg1 |
| CN102532234A (en) * | 2010-12-10 | 2012-07-04 | 北京本草天源药物研究院 | Method for extracting and purifying ginsenoside Rg1 |
| CN102108091B (en) * | 2009-12-28 | 2013-12-25 | 云南本草精素生物科技有限公司 | Method for preparing two ginsenoside monomers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100444370B1 (en) * | 2001-11-27 | 2004-08-16 | 주식회사 한국인삼공사 | The manufacturing method for ginsenoside f1 with naringinase |
| CN100443086C (en) * | 2004-02-06 | 2008-12-17 | 徐琲琲 | New use of ginseng saponin-Re medicine and its preparation method |
| CN100500687C (en) * | 2004-08-04 | 2009-06-17 | 李明劲 | Process for preparing notoginseng triol saponin and use thereof |
| CN1628685A (en) * | 2004-09-07 | 2005-06-22 | 张平 | Medicine combination containing panax pseudo-ginseng saponin triol and preparation method thereof |
| CN1771978B (en) * | 2004-11-09 | 2011-06-08 | 成都华神集团股份有限公司制药厂 | Notoginseng triol-saponin composition and its preparation and use |
-
2008
- 2008-06-06 CN CN2008101146861A patent/CN101597314B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102108091B (en) * | 2009-12-28 | 2013-12-25 | 云南本草精素生物科技有限公司 | Method for preparing two ginsenoside monomers |
| CN102250184A (en) * | 2010-05-21 | 2011-11-23 | 昆明制药集团股份有限公司 | Amorphous state ginsenoside Rg1 and preparation method thereof |
| CN102250184B (en) * | 2010-05-21 | 2013-03-20 | 昆明制药集团股份有限公司 | Amorphous state ginsenoside Rg1 and preparation method thereof |
| CN102453072A (en) * | 2010-10-26 | 2012-05-16 | 中国医学科学院药物研究所 | Preparation method of ginsenoside Rg1 |
| CN102532234A (en) * | 2010-12-10 | 2012-07-04 | 北京本草天源药物研究院 | Method for extracting and purifying ginsenoside Rg1 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101597314B (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100569219C (en) | A kind of pharmaceutical composition that is used for oral formulations and preparation method thereof | |
| CN101311160B (en) | Method for preparing red sage root salviandic acid A | |
| CN100490795C (en) | Red sage root salvianolic acid A injection formulation for treating cardiovascular diseases and preparation process thereof | |
| CN101230003B (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN101597314B (en) | Preparation method of ginsenoside Rg1 | |
| CN101006984B (en) | An injection preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN101283999B (en) | Medicinal composition mainly for curing cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101301300A (en) | Medicament composition | |
| CN101759672B (en) | Salvianolic acid B in radix salviae miltiorrhizae | |
| CN101006975B (en) | An oral medicine preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN101292987B (en) | Pharmaceutical combination | |
| CN101428050B (en) | Active composition for treating thrombus, cardio-cerebrovascular system diseases | |
| CN102085206B (en) | Medicinal composition | |
| CN102086223B (en) | Method for preparing ginsenoside Rg1 | |
| CN101445544B (en) | Method for preparing ginsenoside Rb<1> | |
| CN101361728B (en) | Salvianolic acid A injection and preparation method thereof | |
| CN101390871B (en) | Ginsenoside Rb1 containing impurity ginsenoside Rd | |
| CN101293009A (en) | Pharmaceutical composition | |
| CN1994277B (en) | Solid preparation of salvianolic acid A of red sage root and preparation process thereof | |
| CN101759751A (en) | Ginsenoside Rg 1 containing ginsenoside Re impurity | |
| CN101019878B (en) | Injection medicine composite containing salvianolic acid A and its preparation | |
| CN101696166B (en) | Preparation method for danshen root salvianolic acid A | |
| CN103919759A (en) | Pharmaceutical composition comprising salvianic acid a sodium and salvianolic acid F and preparation of pharmaceutical composition | |
| CN109303785A (en) | A kind of application of lobetyolin's similar compound in preparation treatment arrhythmia cordis drug | |
| CN101390870A (en) | Ginsenoside Rb1 containing impurity ginsenoside Rc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Bencao Tianyuan Pharmaceutical Research Inst., Beijing Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Bencao Tianyuan Pharmaceutical Research Inst., Beijing Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120104 Termination date: 20180606 |